A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

• Non-Small-Cell Lung Carcinoma
• Adenocarcinoma

• Drug: Bevacizumab
  
  Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
  Other Name: Avastin
• Drug: Carboplatin
  
  Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
• Drug: Paclitaxel
  
  Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
• Drug: AG-013736 (axitinib)
  
  AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
  Other Name: axitinib Taxol

• Active Comparator: B
  
  Bevacizumab will be administered in combination with carboplatin and paclitaxel.
  Interventions:
  

  • Drug: Bevacizumab
  • Drug: Carboplatin
  • Drug: Paclitaxel
• Experimental: A
  
  AG-013736 will be administered in combination with carboplatin and paclitaxel.
  Interventions:
  

  • Drug: AG-013736 (axitinib)
  • Drug: Carboplatin
  • Drug: Paclitaxel

Inclusion Criteria:

• Advanced non squamous cell, lung cancer
• No prior treatment for lung cancer except prior adjuvant therapy if last dose was >12 months prior to enrollment

Exclusion Criteria:

• Prior therapy for advanced lung cancer
• The need for blood-thinners
• Coughing up blood